Derrick Siu

Dr. Derrick Siu

University of Sydney, Sydney, New South Wales, Australia
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2013 in Heart
Verified
Journal Article
Open access
PDF file
CMC Raina MacIntyre
C Raina MacIntyre
AHAnita E Heywood
Anita E Heywood
PKPramesh Kovoor
Pramesh Kovoor
IRIman Ridda
Iman Ridda
HSHolly Seale
Holly Seale
DDDominic E Dwyer
Dominic E Dwyer
Background Abundant, indirect epidemiological evidence indicates that influenza contributes to all-cause mortality and cardiovascular hospitalisations with studies showing increases in acute myocardial infarction (AMI) and death during the influenza season. Objective To investigate whether influenza is a significant and unrecognised underlying precipitant of AMI. Design Case-control study. Setting Tertiary referral hospital in Sydney, Australia, during 2008 to 2010. Patients Cases were inpatients with AMI and controls were outpatients without AMI at a hospital in Sydney, Australia. Main outcome measures Primary outcome was laboratory evidence of influenza. Secondary outcome was baseline self-reported acute respiratory tract infection. Results Of 559 participants, 34/275 (12.4%) cases and 19/284 (6.7%) controls had influenza (OR 1.97, 95% CI 1.09 to 3.54); half were vaccinated. None were recognised as having influenza during their clinical encounter. After adjustment, influenza infection was no longer a significant predictor of recent AMI. However, influenza vaccination was significantly protective (OR 0.55, 95% CI 0.35 to 0.85), with a vaccine effectiveness of 45% (95% CI 15% to 65%). Conclusions Recent influenza infection was an unrecognised comorbidity in almost 10% of hospital patients. Influenza did not predict AMI, but vaccination was significantly protective but underused. The potential population health impact of influenza vaccination, particularly in the age group 50–64 years, who are at risk for AMI but not targeted for vaccination, should be further explored. Our data should inform vaccination policy and cardiologists should be aware of missed opportunities to vaccinate individuals with ischaemic heart disease against influenza.

9 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
LKLawrence Kasherman
Lawrence Kasherman
DSDerrick Siu
Derrick Siu
RWRachel Woodford
Rachel Woodford
CHCarole A. Harris
Carole A. Harris
Angiogenesis inhibitors have been adopted into the standard armamentarium of therapies for advanced-stage renal cell carcinomas (RCC), but more recently, combination regimens with immune checkpoint inhibitors have demonstrated better outcomes. Despite this, the majority of affected patients still eventually experience progressive disease due to therapeutic resistance mechanisms, and there remains a need to develop novel therapeutic strategies. This article will review the synergistic mechanisms behind angiogenesis and immunomodulation in the tumor microenvironment and discuss the pre-clinical and clinical evidence for both clear-cell and non-clear-cell RCC, exploring opportunities for future growth in this exciting area of drug development.

1 April 2020 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
LKLawrence Kasherman
Lawrence Kasherman
DSDerrick Siu
Derrick Siu
KLKirsty Wai Chung Lee
Kirsty Wai Chung Lee
SLSally Lord
Sally Lord
IMIan Marschner
Ian Marschner
CLChee Khoon Lee
Chee Khoon Lee

1 February 2024 in JCO Precision Oncology
Verified
Journal Article
Closed access
DSDerrick Siu
Derrick Siu
FLFrank P.Y. Lin
Frank P.Y. Lin
DCDoah Cho
Doah Cho
SLSarah J. Lord
Sarah J. Lord
GHGillian Heller
Gillian Heller
CLChee Khoon Lee
Chee Khoon Lee
Advances in genomics have enabled anticancer therapies to be tailored to target specific genomic alterations. Single-arm trials (SATs), including those incorporated within umbrella, basket, and platform trials, are widely adopted when it is not feasible to conduct randomized controlled trials in rare biomarker-defined subpopulations. External controls (ECs), defined as control arm data derived outside the clinical trial, have gained renewed interest as a strategy to supplement evidence generated from SATs to allow comparative analysis. There are increasing examples demonstrating the application of EC in precision oncology trials. The prospective application of EC in conducting comparative studies is associated with distinct methodological challenges, the specific considerations for EC use in biomarker-defined subpopulations have not been adequately discussed, and a formal framework is yet to be established. In this review, we present a framework for conducting a prospective comparative analysis using EC. Key steps are (1) defining the purpose of using EC to address the study question, (2) determining if the external data are fit for purpose, (3) developing a transparent study protocol and a statistical analysis plan, and (iv) interpreting results and drawing conclusions on the basis of a prespecified hypothesis. We specify the considerations required for the biomarker-defined subpopulations, which include (1) specifying the comparator and biomarker status of the comparator group, (2) defining lines of treatment, (3) assessment of the biomarker testing panels used, and (4) assessment of cohort stratification in tumor-agnostic studies. We further discuss novel clinical trial designs and statistical techniques leveraging EC to propose future directions to advance evidence generation and facilitate drug development in precision oncology.

24 March 2022 in Immunotherapy
Verified
Journal Article
Closed access
DSDerrick Siu
Derrick Siu
RORobert Sean O’neill
Robert Sean O’neill
CHCarole A Harris
Carole A Harris
JWJustine Wang
Justine Wang
LALuke Ardolino
Luke Ardolino
HSHussein Soudy
Hussein Soudy
Immune checkpoint inhibitors have been incorporated into the treatment of various malignancies. An increasing body of literature is reporting rare but potentially fatal adverse events associated wi... Plain language summary Cancer immunotherapy is used in the treatment of different cancer types. Immunotherapy activates the immune system to detect and attack cancer cells, but side effects may ari...

30 January 2022 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
DSDerrick Siu
Derrick Siu
AAARWA ABDELMOGOD
ARWA ABDELMOGOD
ATAngelina Tjokrowidjaja
Angelina Tjokrowidjaja
MSMadhawa De Silva
Madhawa De Silva
JLJoanna Lee
Joanna Lee
LCLorraine A. Chantrill
Lorraine A. Chantrill